China Alport Syndrome Therapeutics market size stood at around USD xx billion in 2020 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.
Alport syndrome (AS), also known as hereditary progressive nephritis, is characterized by haematuria, proteinuria, and progressive renal dysfunction. Some patients may have extrarenal manifestations such as sensorineural deafness and eye abnormalities. The onset of the disease is usually before the age of 10, and some children develop end-stage renal disease in adolescence. Globally X-linked genetic changes account for about 85% of all Alport syndrome and 15% of cases of Alport syndrome have autosomal recessive inheritance caused by two mutations in COL4A3 or COL4A4. The global prevalence of Alport syndrome is estimated to be 1 in every 50,000 live births.
China is a growing market for Alport syndrome due to factors such as increase in global prevalence rate (1 in every 50,000 live births). In addition to this, other factors that contribute to the growth of market are rise in healthcare expenditure, increase in R&D activities and increase in high blood pressure problems (In China about 270 million people have hypertension).
However, there are some restraining factors for the growth of Alport syndrome therapeutics market in China such as high cost of treatment and lack of novel therapeutics for treatment.